In last trading session, Relmada Therapeutics Inc (NASDAQ:RLMD) saw 0.38 million shares changing hands with its beta currently measuring 0.19. Company’s recent per share price level of $0.27 trading at -$0.01 or -1.27% at ring of the bell on the day assigns it a market valuation of $9.04M. That closing price of RLMD’s stock is at a discount of -1785.19% from its 52-week high price of $5.09 and is indicating a premium of 11.11% from its 52-week low price of $0.24. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.45 million shares which gives us an average trading volume of 967.36K if we extend that period to 3-months.
For Relmada Therapeutics Inc (RLMD), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Upright in the red during last session for losing -1.27%, in the last five days RLMD remained trading in the red while hitting it’s week-highest on Thursday, 04/03/25 when the stock touched $0.27 price level, adding 17.15% to its value on the day. Relmada Therapeutics Inc’s shares saw a change of -47.62% in year-to-date performance and have moved -8.19% in past 5-day. Relmada Therapeutics Inc (NASDAQ:RLMD) showed a performance of -0.18% in past 30-days. Number of shares sold short was 1.49 million shares which calculate 3.02 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 96.14% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -640.74% in reaching the projected high whereas dropping to the targeted low would mean a loss of -640.74% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.68% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 64.15% while estimates for its earnings growth in next 5 years are of 35.23%.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
Insiders are in possession of 7.28% of company’s total shares while institution are holding 27.08 percent of that, with stock having share float percentage of 29.20%. Investors also watch the number of corporate investors in a company very closely, which is 27.08% institutions for Relmada Therapeutics Inc that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at RLMD for having 1.23 million shares of worth $3.7 million. And as of 2024-06-30, it was holding 16.3686 of the company’s outstanding shares.
The second largest institutional holder is VESTAL POINT CAPITAL, LP, which was holding about 1.2 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.9076 of outstanding shares, having a total worth of $3.6 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 851.92 shares of worth $0.23 million or 8.61% of the total outstanding shares. The later fund manager was in possession of 456.4 shares on Jan 31, 2025 , making its stake of worth around $0.12 million in the company or a holder of 4.61% of company’s stock.
